Association between HTLV-I Infection and Chronic Lupoid Leishmaniasis

Authors

1 Cutaneous Leishmanaisis Research Center,Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 HTLV-I Foundation, Immunology Department, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Department of Social Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Keywords


Lupi O. Protozoa and worms. In: Bolognia JL, Jorizzo JL, Rapini

RO, Schaffer JV, editors. Dermatology. 2th ed. Spain: Mosby Elsevier;

2008. Vol 1.p.1263-1290.

2. Oumeish OY. Cutaneous leishmaniasis: a historical perspective.

Clin Dermatol 1999 ;17:249-254.

3. Asilian A, Iraji F, Hedaiti HR, Siadat AH, Enshaieh S. Carbon dioxide

laser for the treatment of lupoid cutaneous leishmaniasis

(LCL): a case series of 24 patients. Dermatol Online J 2006; 12:3.

4. Vega Lopez F, Hay RJ. Parasitic worms and protozoa. In: Burns T,

Breathnach S, Cox N, Griffiths C, editors. Rook’s text book of dermatology.

8 th ed.USA: Blackwell Science; 2010. Vol 2 p.37.1-44.

5. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi

A. Comparison of the immune profile of nonhealing cutaneous

Leishmaniasis patients with those with active lesions and those

who have recovered from infection. Infect Immun 2000; 68:1760-

1764.

6. Stefanidou MP, Antoniou M, Koutsopoulos AV, Neofytou YT,

Krasagakis K, Kruger-Krasagakis S,

et al.

A rare case of leishmaniasisrecidivacutis

evolving for 31 years caused by Leishmaniatropica.

 

Int J Dermatol 2008; 47:588-589.

 

7. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F,

 

Bidkhori HR, Shamsian SK, Ahmadi S,

 

 

et al

. High prevalence of

HTLV-I infection in Mashhad, Northeast Iran: a population-based

 

seroepidemiologysurvey. J Clin Virol 2011; 52:172-176.

 

8. Nakada K, Yamaguchi K, Furugen S, Nakasone T, Nakasone K, Oshiro

 

Y,

 

 

et al.

Monoclonal integration of HTLV-I proviral DNA in

patients with strongyloidiasis. Int J Cancer 1987; 40:145-148.

 

9. Goncalves DU, Guedes AC, Proietti AB, Martins ML, Proietti FA,

 

Lambertucci JR,

 

 

et al.

Dermatologic lesions in asymptomatic

blood donors seropositive for human T cell lymphotropic virus

 

type-1. Am J Trop Med Hyg 2003; 68:562-565.

 

10. Lenzi ME, Cuzzi-Maya T, Oliveira AL, Andrada-Serpa MJ, Araujo AQ.

 

Dermatological findings of human T lymphotropic virus type 1

 

(HTLV-I)-associated myelopathy/tropical spastic paraparesis.

 

Clin Infect Dis 2003; 36:507-513.

 

 

283

HTLV-I Infection and Chronic Lupoid Leishmaniasis Pezeshkpoor F et al

Iran J Basic Med Sci; Vol. 16, No. 3, Mar 2013

11. Kuroda Y, Takashima H. Impairment of cell –mediated immune

response in HTLV-I associated myelopathy. J Neurol Sci 1990;

100:211-216.

12. Lenis AM, Blank A, Valderrama L, Saravia NG. Relationship between

the human T-lymphotropic virus type 1 infection and

clinical manifestations of tegumentary leishmaniasis in the Colombian

Pacific Coast. Mem Inst Oswaldo Cruz 1999; 94:19-20.

13. Meymandi S, Dabiri S, Shamsi-Meymandi M, Nikpour H, Kharazmi

A. Immunophenotypic pattern and cytokine profiles of dry

type cutaneous leishmaniasis. Arch Iran Med 2009; 12:371-376.